EirGenix Makes Progress With Trastuzumab Biosimilar
Company Plans To Submit Filings To Both FDA and EMA
Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent.
